Search Website
The Cooperative Trials Group for Neuro-Oncology (COGNO) was established in 2007, following identification of a need to develop a central mechanism enabling a coordinated, structured approach to the management of large scale multi-centred neuro-oncology trials.
COGNO is a member of the Cooperative Clinical Trials Groups of the Clinical Oncological Society of Australia (COSA) and has a close working relationship with the COSA Neuro-Oncology Group. COGNO is funded by Cancer Australia. The group is located at the National Health and Medical Research Council (NHMRC) Clinical Trials Centre (CTC), at the University of Sydney. The NHMRC CTC coordinates the trials activity within COGNO.
COGNO's main aim is to conduct investigator-initiated and collaborative group trials addressing important clinical questions in patients with brain tumours.
Interview with COGNO's 800th Member 
COGNO has reached an important milestone, celebrating its 800th member! To mark this special occasion, COGNO Chair Associate Professor Eng-Siew Koh, has a "Q&A" session with Dr Peter Lau, Medical Oncologist from Sir Charles Gairdner Hospital, WA.
Watch the 10 minute interview here.

Ideas or Concepts

COGNO is interested in developing new concepts into protocols and translating these into clinical research.

If you have a concept you are interested in developing, please complete this online form.

Recent News

21/12/2022: COGNO Newsletter Issue 41 now available

Issue 41 of the COGNO Member Newsletter (Summer 2022 Edition) is now available. Please note the COGNO office is closed from Friday 23 December 2022, re-opening Monday 9 January 2023. We wish everyone a Happy Festive Season and New Year.

14/04/2022: COGNO Newsletter Issue 39 now available

Issue 39 of the COGNO Member Newsletter (Autumn 2022 Edition) is now available for download from the COGNO Newsletters page.

12/01/2022: COGNO: MRFF grant success - the LUMOS2 study

Congratulations to the lead investigator Professor Hui Gan and the co-investigator team for their recent grant success in being awarded $1.98 million for the LUMOS2 (Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS) study, announced this week under the MRFF 2021 Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) grant opportunity.